Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial

Blood Cancer Discovery 2026 Open access

Read full text
Authors: Jayastu Senapati, Hagop M. Kantarjian, Edward Ayoub, Andres Ernesto Quesada, Sanam Loghavi, Koji Sasaki, Tapan Mahendra Kadia, Naval Guastad Daver, Courtney Denton Dinardo, Akhil Jain, Mikaela McCabe, Fadi G. Haddad
+9 more Mark Brandt, Guilin Tang, Yesid Alvarado, Kayla Farish, Hussein A. Abbas, Guillermo Garcia‐Manero, Farhad Ravandi, Michael Andreeff, Gautam M. Borthakur
DOI: 10.1158/2643-3230.bcd-25-0477
Cited by: 1
References: 37

Abstract

Fludarabine, cytarabine, and G-CSF-based therapy (FLAG) yields approximately 60% 5-year overall survival (OS) in core-binding factor (CBF) acute myeloid leukemia (AML), with potential added benefit with gemtuzumab ozogamicin (GO). Although measurable residual disease (MRD) status via optimal quantitative polymerase chain reaction (qPCR) response (OPR; qPCR

Fields of Study & Subjects

Acute Myeloid Leukemia Research Myeloproliferative Neoplasms: Diagnosis and Treatment Acute Lymphoblastic Leukemia research

Publication details

Journal / source
Blood Cancer Discovery
Publisher
American Association for Cancer Research (AACR)
Volume
7
Issue
4
Pages
572–585
Publication date
14 April 2026
Language
EN